BRAF and colorectal carcinoma: When compared with recognized prognostic biomarkers, such as dMMR status or BRAF status in CRC, which have been demonstrated in phase III clinical studies with elements such as randomization, large sample size, robust data, and high credibility [[64], [65], [66]], the prospect of HOXC6 as a promising biomarker for CRC must be demonstrated in additional clinical and mechanistic studies.